Publications by authors named "Johana Mogollon"
Article Synopsis
- The study investigated how leptin's role influences metabolic issues in schizophrenia patients treated with clozapine, focusing on genetic variations in leptin-related genes.
- The research comprised two phases: first, analyzing the metabolic profiles and genetic SNPs of 56 patients; second, assigning 52 of these patients to receive either metformin or placebo for 14 weeks.
- Results indicated that while certain triglyceride levels were lowest in one genetic group, metformin treatment led to increased glucose levels in one genotype and a decrease in metabolic indicators in another, revealing complex responses based on genetic variations.
Background: Clozapine is the most effective agent in treatment-resistant schizophrenia. However, it is frequently associated with excessive body weight (BW) gain, type 2 diabetes mellitus and hyperlipidemia. The antidiabetic metformin (MET) has proved effective to assist in BW control during olanzapine administration.
View Article and Find Full Text PDF